AACR 2021 | TG6002, an oncolytic virus induces expression of a pro-drug activating enzyme in advanced GI cancers

Kaidre Bendjama, Transgene, Strasborg, France, presents the findings of an ongoing Phase I study evaluating oral flucytosine (5-FC) in combination with TG6002, an oncolytic virus encoding FCU1, an enzyme that converts 5-FC to 5-FU, in patients with gastrointestinal carcinomas. TG6002 is found to locate to tumors following intravenous administration, remains active, and effectively expresses FCU1 in tumor tissue, and the study evaluating TG6002 is continuing with escalating doses of virus. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.